Statin Therapy Management

Introduction to Statin Therapy

• Statin therapy is recommended for cardiovascular risk reduction, with benefits generally outweighing the low risk of clinically significant hepatotoxicity in most patients, as stated by the American College of Cardiology 1

Monitoring and Discontinuation

• Baseline hepatic transaminase levels (ALT/AST) should be obtained before initiating statin therapy, and baseline CK levels should be obtained to interpret potential future laboratory results, as recommended by the American College of Physicians and the American College of Cardiology 2, 3, 4, 5, 6
• The American College of Cardiology recommends obtaining CK levels to rule out muscle injury as the source of AST elevation in patients with AST elevation >5× ULN 7
• The American College of Cardiology suggests monitoring AST levels until normalization, typically within 2 months, after statin discontinuation 1
• Regular monitoring of liver enzymes is not recommended for asymptomatic patients on statins, as stated by the American College of Physicians and the FDA 6
• The American College of Cardiology recommends stopping statin therapy if liver enzyme elevation is greater than 5 times the Upper Limit of Normal (ULN) or if there is bilirubin elevation 1

Rechallenge and Dose Adjustment

• The American College of Cardiology recommends rechallenging with the same statin at a lower dose, or trying an alternative statin, such as pravastatin or rosuvastatin, which have less hepatic metabolism, once AST normalizes 7, 1
• The American College of Cardiology suggests gradually increasing the statin dose as tolerated if AST remains normal after rechallenge 1, 2
• The following table outlines the recommended actions for liver enzyme elevation:

8, 9

Safety Considerations

• Statins are generally safe for patients with stable liver disease, with elevated hepatic transaminases occurring in only 0.5% to 2.0% of cases, and progression to liver failure specifically due to statins being exceedingly rare, as reported by the American College of Cardiology 10
• Elevated hepatic transaminases (ALT and/or AST) occur in 0.5% to 2.0% of patients on statins, with these elevations being typically dose-dependent, appearing soon after initiation, transient, asymptomatic, and resolving with continued therapy or brief interruption, as reported by the American College of Cardiology 10, 3
• Statins have not been shown to worsen outcomes in persons with chronic hepatitis B or C, and may improve transaminase elevations in individuals with non-alcoholic fatty liver disease (NAFLD), as reported by the American College of Cardiology 10, 3, 11, 12, 13
• Concomitant use of statins with cyclosporine may increase risk of myopathy and potential liver effects, and requires cautious use, as recommended by the European Association for the Study of the Liver 10, 14, 15, 9, 14
• Statins are contraindicated in decompensated cirrhosis or acute liver failure, and simvastatin should be avoided in advanced liver disease, particularly in patients with MELD score >12 and/or Child-Pugh class C, as reported by the National Institutes of Health and the American Heart Association, and atorvastatin is contraindicated in acute liver failure or decompensated cirrhosis, according to the FDA labeling 4, 5, 8, 15, 4, 5

Alternative Therapies

• Ezetimibe may be considered as an alternative to statins, with a standard dose of 10 mg once daily, and is recommended by the American College of Cardiology as the first-line antihyperlipidemic agent for patients with abnormal liver function due to its favorable safety profile and minimal hepatic metabolism 16
• Fibric acid derivatives have shown no effects on liver histology or liver function in patients with non-alcoholic fatty liver disease (NAFLD) 17
• Omega-3 fatty acids may be considered as an adjunctive therapy for patients with hypertriglyceridemia 17

Special Populations

• Patients with advanced age, small body frame and frailty, multisystem disease, and multiple medications are at increased risk for adverse effects of statin therapy, and should be monitored accordingly, as recommended by the American College of Cardiology 3, 10, 8
• Statins may be used in patients with chronic, stable liver disease, including NAFLD, after obtaining baseline measurements and determining an appropriate monitoring schedule, with a moderate strength of evidence, as recommended by the American College of Cardiology 11, 12, 13
• Reinforce weight loss counseling and recommend increased physical activity for NAFLD management, and consider reduced saturated fat intake, limited cholesterol intake, and reduced carbohydrate and alcohol consumption for patients with hyperlipidemia and fatty liver disease, as recommended by the American Association for the Study of Liver Diseases and the American Diabetes Association 12, 18